
    
      We plan to examine how successful treatment with the current standard treatment of pegylated
      interferon and ribavirin is in those who continue to use injection drugs. Our goal is to
      determine whether reasonable success rates can be achieved in active drug users that would
      then further justify their routine treatment.
    
  